导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.78% | 1049/4773 |
| 近一周 | -2.28% | 1660/5462 |
| 近一月 | -8.21% | 4155/5421 |
| 近一季 | -6.45% | 2096/5209 |
| 近半年 | -0.41% | 1292/4920 |
| 近一年 | 14.10% | 739/4366 |
| 近两年 | 103.06% | 584/2954 |
| 近三年 | 78.83% | 223/2253 |
| 成立以来 | 79.85% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.08% 2116/4961 |
29.94% 1008/5312 |
- - |
- - |
| 2025 | 52.86% 400/4813 |
2.37% 1391/3635 |
2.87% 1299/4076 |
44.66% 624/4524 |
0.34% 2055/4813 |
| 2024 | 13.02% 1187/3463 |
-1.22% 1199/2808 |
-0.10% 679/3014 |
11.49% 2512/3129 |
2.74% 896/3463 |
| 2023 | -1.41% 510/2656 |
14.97% 225/2280 |
0.17% 337/2385 |
-10.76% 2019/2515 |
-4.06% 858/2655 |
| 2022 | -23.94% 1178/2207 |
-17.57% 1218/1919 |
4.64% 986/2016 |
-15.01% 1189/2113 |
3.75% 651/2208 |
| 2021 | 20.31% 181/1822 |
-3.41% 805/1255 |
17.63% 182/1330 |
-0.25% 483/1466 |
6.16% 230/1822 |
| 2020 | - - |
- - |
- - |
- - |
- - |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 天弘中证科技100指数增强发起A VS. 长安沪深300非周期A(740101) |